Logo

ELTX

Elicio Therapeutics, Inc.

ELTX

Elicio Therapeutics, Inc. • NASDAQ
$9.36 ▲ 2.18% (+0.20)
Market Cap $161.54 M
52w High $12.62
52w Low $4.60
Dividend Yield 0%
P/E -3.01
Volume 37.11K
Outstanding Shares 17.26M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $7.762M ▼ $-10.083M ▲ 0% $-0.6 ▲ $-9.374M ▲
Q2-2025 $0 $10.091M ▼ $-10.561M ▲ 0% $-0.66 ▲ $-10.086M ▲
Q1-2025 $0 $10.458M ▼ $-11.209M ▲ 0% $-0.87 ▲ $-10.755M ▲
Q4-2024 $0 $13.171M ▲ $-14.004M ▲ 0% $-1.15 ▲ $-13.465M ▲
Q3-2024 $0 $10.054M $-18.838M 0% $-1.39 $-18.411M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $20.611M ▼ $28.284M ▼ $24.468M ▼ $3.816M ▲
Q2-2025 $22.088M ▲ $29.528M ▲ $27.694M ▲ $1.834M ▼
Q1-2025 $18.351M ▲ $28.144M ▼ $19.24M ▼ $8.904M ▲
Q4-2024 $17.618M ▼ $28.178M ▼ $39.49M ▼ $-11.312M ▲
Q3-2024 $26.016M $38.388M $57.374M $-18.986M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-10.083M ▲ $-11.086M ▼ $0 $9.572M ▼ $-1.477M ▼ $-11.086M ▼
Q2-2025 $-10.561M ▲ $-8.95M ▲ $0 $11.932M ▲ $3.056M ▲ $-8.95M ▲
Q1-2025 $-11.209M ▲ $-10.119M ▼ $0 ▲ $10.328M ▲ $240K ▲ $-10.119M ▼
Q4-2024 $-14.004M ▲ $-8.744M ▼ $-45K ▼ $227K ▼ $-8.535M ▼ $-8.789M ▼
Q3-2024 $-18.838M $-7.274M $0 $30.754M $23.516M $-7.274M

Five-Year Company Overview

Income Statement

Income Statement Elicio is still a pure research-stage biotech, with essentially no commercial revenue so far. The income statement shows recurring operating and net losses each year, which is normal for a company funding clinical trials without products on the market. Losses have stayed relatively modest in absolute size but have not narrowed meaningfully, reflecting ongoing investment in development rather than any turn toward profitability. The bottom line is that the business model is currently all cost and no revenue, with future results heavily dependent on clinical and partnering milestones rather than current operations.

Balance Sheet

Balance Sheet The balance sheet is small and somewhat fragile. Assets are limited and mostly made up of cash, with very little in the way of physical or long-lived assets. Debt has increased recently, and shareholder equity has swung between slightly positive and slightly negative, signaling a thin financial cushion. This structure is typical for an early-stage biotech but leaves limited room for setbacks without new funding or restructuring of obligations.

Cash Flow

Cash Flow Cash flow is consistently negative, driven by operating expenses for research and trials, with no offsetting inflows from product sales. Free cash flow mirrors operating cash flow because capital spending is minimal, underscoring a lean, lab-focused model rather than heavy infrastructure build-out. The cash burn appears relatively steady but, given the small cash base, the company’s funding runway is likely constrained and will depend on additional capital raises, partnerships, or other financing. This reliance on external funding is a central financial risk factor.

Competitive Edge

Competitive Edge Elicio operates in a very crowded and high-stakes immuno-oncology field, competing against much larger and better-funded players. Its main differentiator is the Amphiphile platform, designed to deliver cancer vaccines more efficiently to lymph nodes and potentially generate stronger immune responses. The focus on “off‑the‑shelf” vaccines for common mutations like KRAS could offer advantages in speed, scalability, and cost compared with fully personalized approaches. However, the company remains small, clinical data are still developing, and big pharma competitors are targeting many of the same mutations, so its long-term competitive standing is not yet established.

Innovation and R&D

Innovation and R&D Innovation is clearly the core strength of Elicio. The Amphiphile platform is a novel, lymph node–targeted delivery technology with broad potential across multiple cancer types and possibly other diseases. The lead KRAS vaccine, along with early programs against BRAF and p53, shows how the same platform can be reused across several high-value cancer mutations, creating a scalable R&D engine rather than one-off products. Early clinical results for the lead asset are encouraging but still preliminary; the true test will be later-stage trials and the company’s ability to turn scientific promise into clear, replicated patient benefit. R&D intensity is high by design, which is strategically positive but also drives continuing financial losses and funding needs.

Summary

Overall, Elicio is a classic clinical-stage biotech story: scientifically ambitious, financially thin, and highly dependent on future trial outcomes. The company has no current product revenue and runs persistent losses, sustained by a small asset base and increasing reliance on financing. Its main attraction lies in a differentiated immuno-oncology platform and an “off‑the‑shelf” cancer vaccine strategy aimed at common, hard-to-treat mutations. The main risks are scientific (can the platform succeed in larger, controlled trials?), competitive (can it stand out against much larger rivals?), and financial (can it secure enough capital to reach key milestones?). Outcomes for shareholders are therefore likely to be highly sensitive to clinical data, partnership activity, and access to funding over the next few years.

NEWS

November 19, 2025 · 8:00 AM UTC

Elicio Therapeutics Appoints Veteran CMC and Technical Operations Executive Marc J. Wolfgang as Chief Technology Officer

Read more

November 13, 2025 · 4:01 PM UTC

Elicio Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

Read more

November 7, 2025 · 9:00 AM UTC

Elicio Therapeutics Reports Robust, Cytolytic mKRAS-Specific T Cell Responses Across Diverse Patient HLA in Ongoing Phase 2 AMPLIFY-7P Trial of ELI-002 7P and New ELI-004 Preclinical Data at SITC

Read more

November 3, 2025 · 8:00 AM UTC

Elicio Therapeutics to Present Clinical and Preclinical Data at the SITC 2025 Annual Meeting

Read more

October 27, 2025 · 8:00 AM UTC

Elicio Therapeutics Reports Robust T cell Responses Across Diverse HLA backgrounds in Ongoing Phase 2 AMPLIFY-7P Trial

Read more